Bone Marrow is the soft, sponge-like tissue in the center of most bones. It produces white blood cells, red blood cells, and platelets.
Immune system cells in the blood of breast cancer patients undergo alterations early in the disease course, according to a study.
Acute myeloid leukemia is an aggressive cancer of the blood-forming system. It affects the hematopoietic stem cells, or blood stem cells, of various white blood cells and of the red blood cells and platelets.
A new study released today in STEM CELLS suggests for the first time that regulatory T-cells (Treg) induced by mesenchymal stromal cells can yield an abundant replacement for naturally occurring T-cells, which are vital in protecting the body from infection.
Before multiple myeloma becomes a malignant disease, the collection of immune system cells and signal carriers amid the tumor cells undergo dramatic shifts.
A UCLA-led research team today reports that it has developed a new method for delivering DNA into stem cells and immune cells safely, rapidly and economically.
Sooner or later, most cancer patients develop resistance to chemotherapy drugs designed to kill their cancer, forcing oncologists to seek alternatives.
Human stem cells have been typically perceived as one of the potential cell sources for cardiac regeneration treatment. However, the substandard performance following transplantation into the failing hearts has limited their applications in clinical use.
Stem cells are capable of producing a wide range of particular tissues and are used more and more in clinical applications—for example, these cells are used for replacing a cartilage or bone.
A Franco-German research team led by Prof. Michael Sieweke, from the Center for Regenerative Therapies TU Dresden and the Center of Immunology of Marseille Luminy, today uncovered a surprising property of blood stem cells: not only do they ensure the continuous renewal of blood cells and contribute to the immune response triggered by an infection, but they can also remember previous infectious encounters to drive a more rapid and more efficient immune response in the future.
A team of Australian researchers has confirmed the feasibility and potential of applying integrated lipidomics and proteomics to malignant plasma cells from myeloma patients.